文献速递胸部肿瘤

KEAP1突变型非小细胞肺癌:细胞保护枢纽的灾难性失效

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
PubMed 文献 · J Thorac Oncol · 2022-03-26

KEAP1-NRF2通路突变在非小细胞肺癌中常见,KEAP1突变在肺腺癌中有一定患病率,肺鳞癌中KEAP1与NFE2L2改变比例相当。该通路调控细胞稳态与细胞保护反应,KEAP1突变与化疗、放疗及靶向治疗耐药相关,KEAP1突变肺腺癌呈免疫冷肿瘤微环境且免疫治疗疗效降低,但KEAP1与免疫耐药的关系更复杂并依赖共存基因组改变。

要点

  • KEAP1-NRF2通路是细胞稳态与氧化应激耐受的关键调控枢纽。
  • KEAP1突变与化疗、放疗及靶向药物耐药相关。
  • KEAP1突变肺腺癌呈免疫冷微环境,免疫治疗疗效降低,但关系依赖共存基因组改变。

核心结论

  • KEAP1-NRF2通路失调在肺癌中具有临床意义,开发针对该通路的抗癌治疗应被视为胸部肿瘤学领域的优先事项。

研究设计与样本

  • 本文为关于KEAP1突变型非小细胞肺癌的综述,未报告系统检索范围。

主要发现

  • KEAP1突变在肺腺癌中有一定患病率,肺鳞癌中KEAP1与NFE2L2改变比例相当。
  • KEAP1-NRF2轴调控细胞耐受氧化与代谢应激及外源性物质,NRF2介导的细胞保护反应包括解毒机制、铁死亡保护和代谢重编程。
  • 多项临床研究将KEAP1突变与化疗、放疗及靶向药物耐药增加相联系。
  • KEAP1突变肺腺癌的典型特征为免疫冷肿瘤微环境,并报告免疫治疗疗效降低。
  • KEAP1与免疫耐药的关系似乎更复杂,并依赖于共存的基因组改变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the KEAP1-NRF2 pathway are common in NSCLC, albeit with a prevalence of KEAP1 mutations in lung adenocarcinoma and an equal representation of KEAP1 and NFE2L2 (the gene encoding for NRF2) alterations in lung squamous cell carcinoma. The KEAP1-NRF2 axis is a crucial modulator of cellular homeostasis, enabling cells to tolerate oxidative and metabolic stresses, and xenobiotics. The complex cytoprotective response orchestrated by NRF2-mediated gene transcription embraces detoxification mechanisms, ferroptosis protection, and metabolic reprogramming. Given that the KEAP1-NRF2 pathway controls core cellular functions, it is not surprising that a number of clinical studies connected KEAP1 mutations to increased resistance to chemotherapy, radiotherapy, and targeted agents. More recently, an immune-cold tumor microenvironment was described as a typical feature of KEAP1-mutant lung adenocarcinoma. Consistently, a reduced efficacy of immunotherapy was reported in the KEAP1-mutant background. Nevertheless, the connection between KEAP1 and immune resistance seems more complex and dependent on coexisting genomic alterations. Given the clinical implications of deregulated KEAP1-NRF2 pathway in lung cancer, the development of pathway-directed anticancer treatments should be considered a priority in the domain of thoracic oncology.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Scalera S, Mazzotta M, Cortile C, et al. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. J Thorac Oncol. 2022. PMID: 35351670. doi:10.1016/j.jtho.2022.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。